Pancreatic Cancer

CYNVILOQ™ in ASCO 2013 Pancreatic Ca. Sorrento Therapeutics, Inc


SAN DIEGO and IRVINE, Calif., May 28, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCBB: SRNE; STI) and IGDRASOL announced today that clinical data for CynviloqTM, a non-biologic nanoparticle formulation of paclitaxel, plus gemcitabine was published for the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO). The abstract (#e15076), entitled "Evaluation of a non-biologic nanoparticle form of paclitaxel in metastatic pancreatic cancer" was chosen for inclusion online in the ASCO 2013 Annual Meeting Proceedings, a Journal of Clinical Oncology supplement, and was released at on May 15, 2013. The abstract was authored by Kouros Motamed, Larn Hwang, Chao Hsiao, and Vuong N. Trieu.


A Phase I clinical trial established a maximum tolerated dose (MTD) for CynviloqTM of 300 mg/m2 when given every 3 weeks in combination with weekly dosing of 1250 mg/m2gemcitabine as first line treatment for patients with advanced pancreatic cancer. Moreover, 5 out of 16 patients (31.3%) had confirmed complete responses (CR) or partial response (PR) with 95% exact confidence intervals (CI) of 11.0 and 58.7, respectively. The median progression-free survival (PFS) time was 5.6 months (95% CI = 2.9). The median overall survival (OS) time could not be estimated as the survival rate did not fall below 50%.


"Based on the data generated to date, we believe CynviloqTM in combination with gemcitabine may offer beneficial dosing regimens and potent anti-tumor activity in patients with advanced pancreatic cancer", said Vuong Trieu, Ph.D., chief executive officer of IGDRASOL.

Brand Name: PAXUS™ PM (South East Asia), GENEXOL® PM (Korea & other territories)